About
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Booth #5D18
06-08 October, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
CONTACT DETAILS
Digital content 
NEWS #PharmaBuzz
03 Apr 2019
// ECONOMIC TIMES
05 Nov 2018
// Beth Snyder Bulik FIERCE PHARMA
23 May 2018
// PATENT LITIGATION
23 May 2018
// PATENT LITIGATION
02 Apr 2018
// BUSINESSWIRE
05 Feb 2016
// FDA
Drugs in Development
Lead Product(s) : DFD-07
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp
Details : DFD-07 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 13, 2016
Lead Product(s) : DFD06
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DFD06 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 18, 2015
Lead Product(s) : DFD-06
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DFD-06 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 15, 2015
Lead Product(s) : DFD06
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DFD06 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 06, 2014
Lead Product(s) : ACT01,Comp02,Comp03
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Details : ACT01 is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 30, 2014
Lead Product(s) : Clocortolone Pivalate
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
Details : Clocortolone Pivalate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2012
Lead Product(s) : NAB001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
Details : NAB001 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Onychomycosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 23, 2010
Lead Product(s) : NAB001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
Details : NAB001 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Onychomycosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 23, 2010
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Dosage Form : CAPSULE; ORAL
Proprietary Name : SECTRAL
Dosage Strength : EQ 200MG BASE **Federal ...
Approval Date : 1984-12-28
Application Number : 18917
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Dosage Form : CAPSULE; ORAL
Proprietary Name : SECTRAL
Dosage Strength : EQ 400MG BASE **Federal ...
Approval Date : 1984-12-28
Application Number : 18917
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : TENEX
Dosage Strength : EQ 1MG BASE **Federal Re...
Approval Date : 1986-10-27
Application Number : 19032
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : TENEX
Dosage Strength : EQ 2MG BASE **Federal Re...
Approval Date : 1988-11-07
Application Number : 19032
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : TENEX
Dosage Strength : EQ 3MG BASE **Federal Re...
Approval Date : 1988-11-07
Application Number : 19032
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : ISMO
Dosage Strength : 20MG
Approval Date : 1991-12-30
Application Number : 19091
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Inspections and registrations
ABOUT THIS PAGE
Promius Pharma
Share 
